First in-human clinical trial of CAR T cell therapy with new ...
Phase I trial of AT101, a novel CAR T cell therapy targeting CD19 differently, shows 100% complete response at higher doses in relapsed/refractory B cell NHL patients, indicating potential for broader efficacy. Findings presented at ASH and published in Molecular Cancer.
Reference News
First in-human clinical trial of CAR T cell therapy with new ...
Phase I trial of AT101, a novel CAR T cell therapy targeting CD19 differently, shows 100% complete response at higher doses in relapsed/refractory B cell NHL patients, indicating potential for broader efficacy. Findings presented at ASH and published in Molecular Cancer.